An Independent Reading of the Literature

What this site is

Pussy Peptide is an editorial research digest on three peptides that intersect the melanocortin and kisspeptin literature: PT-141 (bremelanotide), kisspeptin, and Melanotan II. It exists to summarize, cite, and contextualize published research — animal studies, clinical trials, regulatory documents, and case reports — in plain language a non-specialist reader can follow. It does not sell any compound, does not operate a pharmacy or telehealth service, and does not give medical advice.

Why these three

The site's organizing thread is female sexual-health research within the melanocortin and kisspeptin literature, anchored by bremelanotide's 2019 FDA approval for hypoactive sexual desire disorder — the one point in this space where a peptide cleared a full regulatory review for exactly the effect this site is built around. Kisspeptin and Melanotan II sit alongside it because both are mechanistically connected — one upstream in the reproductive cascade, one a non-selective relative sharing PT-141's chemical backbone — and reading all three together makes the differences in receptor selectivity, regulatory status, and documented safety far easier to see than reading any one in isolation.

How this site reads a study

Every claim on this site traces to a specific, numbered source on the references list — a peer-reviewed journal article, a clinical-trial registry record, an FDA prescribing label, or a documented case report. Findings from animal studies are labeled by species; findings from human trials note the population studied and, where relevant, the trial phase. Community-reported experiences are kept clearly separate from clinical findings and are always labeled anecdotal, not clinical evidence — they describe what people say happened, not a measured outcome.

When a study reports a specific dose, this site states that dose exactly as the study used it, because removing it would misrepresent the research. That is different from a recommendation: nothing on this site tells a reader what to take, and no page implies self-administration is safe or advisable.

What this site does not do

It does not sell peptides, promote a specific vendor, or link to a purchase page. It does not diagnose, prescribe, or recommend a course of treatment for any individual. It does not present community anecdotes as clinical evidence, and it does not omit a documented safety signal because a compound is popular in research-use communities. Where the evidence is thin — as it is for Melanotan II's intended uses, and for kisspeptin's long-term human safety — the site says so directly rather than filling the gap with confidence the literature does not support.